Exploring the Growth Potential of the Indian Pharmaceutical Sector
The Indian pharmaceutical sector has demonstrated a robust growth trajectory, with a notable increase in performance over the past year. The sector has benefitted from a new trade agreement with the European Union, which aims to reduce tariffs on key drug exports. This agreement is expected to enhance India's position as a global supplier of
generic medicines
, leading to increased trade volume and job creation within the sector.
In the short term, the sector has shown positive momentum, reflecting a steady rise in investor confidence. The long-term implications of the trade agreement include improved access to European markets and potential technology transfer, which could significantly bolster India's pharmaceutical
innovation
capabilities. Overall, the outlook for the sector remains positive, with analysts projecting substantial upside potential for various companies operating within this space.
Top Companies Analysts Recommend Based on Upside Potential
Company Name
Current Price
Target Price
Upside Potential
Recommendation
Cohance Lifesciences Limited
Rs. 1065.4
Rs. 1400.00
33%
Strong Buy
Piramal Pharma
Rs. 205.74
Rs. 271.00
32%
Strong Buy
Natco Pharma
Rs. 870.1
Rs. 1090.00
28%
Hold
Aurobindo Pharma
Rs. 1182
Rs. 1470.00
23%
Buy
Blue Jet Healthcare
Rs. 794.3
Rs. 943.00
19%
Buy
Zydus Lifesciences
Rs. 906.65
Rs. 1040.00
18%
Hold
Cohance Lifesciences
Cohance Lifesciences Limited
, formerly known as Suven Pharmaceuticals Limited, is a technology-driven contract development and manufacturing organization(CDMO)based in India. The company specializes in providing integrated solutions in custom synthesis, process research and development, and manufacturing. Its
business
units include pharmaceutical CDMO, specialty chemical CDMO, and active pharmaceutical ingredient(API)services.
Analysts have a strong buy recommendation for Cohance Lifesciences, with a target price of Rs. 1400.00, indicating an upside potential of 33%. The company has shown impressive financial performance, with a year-on-year PAT growth of 77.27%, despite a slight decline in sales growth of 21.56%.
Piramal Pharma
Piramal Pharma
Limited is a global pharmaceutical company offering a diverse portfolio of differentiated pharma products across a domestic and global
distribution
network. The company operates approximately 17 development and manufacturing facilities across India, the UK/Europe, and North America.
With a strong buy recommendation from analysts, Piramal Pharma has a target price of Rs. 271.00, reflecting an upside potential of 32%. The latest financial data shows a sales growth of 11.99% year-on-year, although the PAT stands at Rs. 153.5 Cr.
Natco Pharma
Natco Pharma
Limited is an India-based vertically integrated pharmaceutical company focused on research and development. The company specializes in developing, manufacturing, and commercializing complex pharmaceuticals targeting specific therapeutic areas.
Analysts recommend holding Natco Pharma, with a target price of Rs. 1090.00, indicating an upside potential of 28%. The latest financial results reveal a significant year-on-year sales growth of 47.72%, although PAT has decreased by 37.47% compared to the previous year.
Aurobindo Pharma
Aurobindo Pharma
Limited is engaged in the manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, and generic pharmaceuticals. The company has a global presence, marketing its products in approximately 150 countries.
With a buy recommendation from analysts, Aurobindo Pharma has a target price of Rs. 1470.00, reflecting an upside potential of 23%. The company reported a year-on-year sales growth of 16.68%, although PAT has decreased by 9.66% in the latest quarter.
Blue Jet Healthcare
Blue Jet Healthcare
Limited specializes in manufacturing integrated contrast media, artificial sweeteners, and niche pharmaceutical intermediaries. The company operates primarily as a business-to-business entity, serving various industries globally.
Analysts have a buy recommendation for Blue Jet Healthcare, with a target price of Rs. 943.00, indicating an upside potential of 19%. The company has demonstrated remarkable financial growth, with a year-on-year PAT growth of 177.64% and sales growth of 44.74%.
Zydus Lifesciences
Zydus Lifesciences
Limited is a global life sciences company engaged in discovering, developing, manufacturing, and marketing a broad range of healthcare therapies. The company has a diverse product portfolio, including active pharmaceutical ingredients and human formulations.
Analysts recommend holding Zydus Lifesciences, with a target price of Rs. 1040.00, reflecting an upside potential of 18%. The company has reported a year-on-year sales growth of 18.9%, although PAT has decreased by 5.79% in the latest quarter.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
11 minutes ago
- Mint
From China+1 to India+1: Jolted manufacturers look for business beyond the US
A toy factory floor on the outskirts of Bengaluru is alive with motion and noise. Long rows of assembly lines hum steadily, carrying half-finished cars, dolls, and animal figurines from one station to the next. Workers in safety vests and blue, maroon, and black uniforms move quickly but with practiced rhythm. Some workers spray plastic toy parts in various colours to meet stringent client requirements, while their colleagues fix wheels to trucks. Mountains of cartons are stacked at the edge of the factory floor, ready to be shipped to American buyers ahead of the holiday season. With Thanksgiving and Christmas around the corner, the third quarter is the busiest time of the year. The sense of urgency and excitement on the factory floor contrasts with the gloom in the back office of Propelus Manufacturing, which is offering steep discounts to its American clientele after US President Donald Trump threatened a 50% tariff rate on imports from India. 'Our 2025 orders…the clients will take, but we have to cut rates. We have to support them. Only then they may come back. Clients are hunting for countries with the lowest tariff," said Anshu Arya, who set up this factory post-pandemic, spotting an opportunity in the US pivot from China's factory floor. 'But our 2026 orders of $1.5 million have been halted." 25% tariffs are already in effect. Secondary sanctions, in the form of additional 25% tariffs for India's purchase of Russian oil, are set to kick in on 27 August. Trump may eventually decide against pressing ahead with the additional tariff, but it has already spooked buyers in the US. Even if withdrawn, the new diplomatic reality may make them more cautious about sourcing from India, especially as bilateral relations have soured—close ties with Washington were a key selling point for Indian manufacturers. And even at 25%, India's tariff would remain five percentage points higher than that of its closest competitor, Vietnam. Propelus's LinkedIn page calls it 'A real alternative to China right now." 65% of its revenue is generated from the export market, with the US accounting for 90% of it. 'I was at home that evening. I immediately started getting calls after the US tariff announcement came in. Clients were calling to put orders on hold. Everybody has to save their business. There is nothing I can do, I just have to oblige," said Arya. Case of unfinished shoes The US is the largest consumer market in the world despite being home to only 4% of the world's population. According to Deutsche Bank, it accounts for almost 30% of global consumption. US private consumption is about $19 trillion annually, according to research platform Microtrends, making it the most lucrative and sought-after export market. Labour-intensive manufacturing exports in apparel, textiles, footwear, furniture, toys and gems and jewellery are likely to be the most impacted by US tariffs. The industry functions on thin margins and employs a huge chunk of the manufacturing workforce in the country. According to Crisil, last fiscal, the US accounted for about 20% of India's merchandise exports. About 2,000 kilometres away from Bengaluru, in Agra, Legwork, a footwear contract manufacturer, has seen new US orders dry up. Exports make 60% of sales at Legwork. 'Earlier, sales agents were giving us hope that with China+1, we will get lots of orders. Even Chinese manufacturers were enquiring. Now everything has unravelled," said owner Vijay Nainani. Last year, Legwork shipped a massive order of 300,000 shoes for Costco, a retailer in the US. Without sharing names, he said many in the industry have started shipping unfinished shoes to Vietnam, Cambodia, and Bangladesh, and are tying up with manufacturers there to finish up the final product so as to hide the country of origin and escape US tariffs on India. Raghunandan Saraf, chief executive at Rajasthan-based Saraf Furniture, calls the current uncertainty 'tougher than a bad situation." His top export markets are in Europe, with the US making up for small volumes. Exports make up 55% of total sales. Now, some buyers from the European Union (EU) have also slowed down orders because of global uncertainty and the tariff wars—a double whammy for Indian manufacturers. 'We are seeing a slowdown in orders from the EU," said Saraf. 'Our buyers are apprehensive right now about believing their own forecast. Our importers give us a sales forecast for the next six months, based on which we build our inventory. Right now, they are not confident because of tariffs and wars." Saraf has slowed down production in his factories to avoid a buildup of unsold inventory. 'Give it to Bangladesh' The anguish and anxiety felt by Arya, Saraf, and Nainani are not restricted to small and mid-scale manufacturers in the country. Raymond Ltd, one of India's top textile and apparel manufacturers and exporters, is negotiating the price hit from the tariff fallout with its US clients. 'We are right now dealing with a US customer for whom the fabric is ready in India. He said, take the fabric, give it to Bangladesh, and get it stitched to a simple garment there, and pay only 20% duty. It can be made available before Thanksgiving. For other complicated garments like suits, he has no option but to continue with us," said Amit Agarwal, Raymond's chief financial officer. Agarwal said Raymond might consider ramping up production in its Ethiopia factory for the US market. Ethiopia faces only a 10% tariff. He is not alone in considering a diversification of production outside India as a call of last resort. Godrej Interio, which exports office furniture, is also considering increasing production from its factories in Oman and Vietnam—countries with lower tariffs than India at present. The US has imposed a 10% tariff on Oman and 20% on Vietnam. 'We have manufacturing presence in countries beyond India. We are exploring producing more from these locations. It is a thought in the back of our mind," said Swapneel Nagarkar, executive vice president and business head at Godrej Interio. The 'India+1' plan Alexandra Hermann, an economist with Oxford Economics, is concerned about the impact on India's attractiveness as a manufacturing hub if 50% tariffs were to continue. 'India's appeal as a production and investment alternative to China is shrinking as compared to the already-bigger manufacturing hubs in the rest of Asia, and, in fact, we hear that Indian and global manufacturers are starting to think about 'India+1' strategies now," she said. 'India + 1' means that companies primarily serving the US market will start thinking about moving out of India. India's labour-intensive manufacturing exports have already struggled to compete on the world stage. According to the World Bank, countries such as Vietnam and Bangladesh, and even advanced economies such as Germany and the Netherlands, have become the primary beneficiaries of China's shrinking market share in low-skill manufacturing. The data shows India's share in global exports of apparel, leather, textiles and footwear (ALTF) initially grew from 0.9% in 2002 to a peak of 4.5% in 2013, but it subsequently declined to 3.5% in 2022. In contrast, Vietnam's share has increased to 5.9% and Bangladesh reached 5.1% of global ALTF exports in 2022. India's rigid labour laws, lack of supply chain ecosystem, and high import duties on critical raw materials have kept the cost of production higher than in other Asian economies. Adding punitive tariffs, such as those imposed by the US, makes it close to impossible for India to compete for US orders. Abhishek Ganguly, co-founder of footwear manufacturer Agilitas Sports, said the industry struggles with the lack of raw material supply chain and needs to import top-quality machinery and shoe components from China, among other countries. 'In this industry, seasonality is a big factor, so speed to manufacture and to market is an important success metric. Global brands say India will never be timeline-wise as fast as Vietnam and China," said Ganguly. He is focusing on making in India for the domestic market. In the past decade itself, countries like Vietnam effectively utilized their cost-competitive labour and created a business-friendly environment conducive to manufacturing. The small country has raced ahead due to its first-mover advantage, proximity to China, a strong network of 16 free trade agreements across the globe, enabling investment laws, and simpler labour laws that make scaling factories quicker. In comparison, India's labour-intensive manufacturing is highly fragmented, consisting of small and unscalable factories. They find it difficult to compete in the global market and rely mainly on domestic demand to survive. Battle in a sabzi market The US' pivot from China was a golden opportunity for India to claw some share back. The gap left by the potential retreat of the US, according to manufacturers, won't be an easy one to fill with alternative foreign markets or domestic demand. 'If you don't have the biggest consumer market in the world, how will you become a global leader in manufacturing? Price efficiency only happens with scale, and that can only happen if we make for the US," said Arya. According to Arya's professional experience, American consumers spend up to ₹2,300 on a single toy purchase versus ₹1,800 in the EU and only ₹500 in India. On a per capita basis, India's domestic market is relatively small compared to global markets. According to the Federation of Economic Development, India's domestic clothing market was valued at $55 billion in 2019, whereas the OECD (Organisation for Economic Co-operation and Development) countries collectively imported clothing worth $380 billion—nearly seven times the size of the Indian market. 'Export orders come in bulk and make our lives easier. For Costco, we had to make 300,000 pairs in one design, and it was very easy to make. We bought raw material in bulk at cheap prices. For Indian brands, the order sizes are like 600 pairs, and they fight with us on price like it is a sabzi (vegetable) market," said Legwork's Nainani. Labour-intensive exports are the launchpad for any country aspiring to become a global manufacturing hub. All Asian countries, including China and South Korea, used labour-intensive manufacturing exports to start their factory revolution before moving up the value chain. It helps employ large swaths of the young population and requires relatively less vocational training and capital investment, making it critical for India to scale this sector. 'Domestic demand is still not deep or premium enough to absorb large-scale production profitably," said Ajay Sahai, director general and CEO at the Federation of Indian Export Organisation, the apex body of trade promotion organizations, set up by India's ministry of commerce. 'The domestic market focus should not come at the cost of export ambition. The long-term growth and employment potential of India's labour-intensive manufacturing sector lies in becoming globally competitive," he added. The UK template The challenge is not just the domestic market. For Indian manufacturers to compete for business in other developed economies in Europe is not an easy segue. Multiple small orders are more expensive to produce than one mass order for the US. 'There are so many countries and brands in Europe. And the population in each country is much smaller than the 300 million in the US," said Raymond's Agarwal. 'For a thin margin business like ours, with more complexities, cost is going to inevitably become higher. That is why we love to supply to the US market," he added. According to Sahai, the gestation period for meaningful results from market diversification can range from 18 months to three years, depending on sectoral readiness and policy support. In addition, experts said, India will be competing with many countries that are also looking to diversify away from the US due to high tariffs. So, potential clients have a lot more choice, and may further squeeze margins 'The problem is that, unlike China, India is less integrated into different economies. In the short term, it is going to be hard to figure out what the alternative markets are that we can target. Market development, forming business relationships, and being chosen as a preferred supplier is hard," said Rohit Kumar, founding partner, Quantum Hub, a New Delhi-based public policy consulting firm. Experts believe that India's Free Trade Agreement with the UK provides an excellent template for India to start opening up its economy to the developed world in a graded manner and start competing on the global stage more aggressively. In July, India and the UK sealed a trade deal eliminating tariffs on products ranging from cars to alcohol. Due to the agreement, Indian goods, including textiles, jewellery, agricultural products, and engineering goods, would get better access in the UK market. 'Opening the economy is a need of the hour. You are the 4th largest economy in the world, and if you don't integrate with the global economy, you will suffer," said Vivek Mishra, deputy director of Strategic Studies Programme at the Observer Research Foundation. 'You have a disruptor in President Trump, and he wants some sectors to be opened immediately. That is what is causing a problem."
Economic Times
11 minutes ago
- Economic Times
Astrotalk appoints Deepak Khetan as chief financial officer
Noida-based Astrotalk, a startup that provides astrology consulting services, has appointed Deepak Khetan as its chief financial officer, as it plans to go public within the next two years, the company said on Monday. Khetan joins Astrotalk after having served as the CFO in organisations such as GLS Group India, GlobalBees, and Edelweiss Financial Services Limited. In his new role, he will oversee financial planning, risk management, compliance, and investor relations. Khetan will also be responsible for preparing Astrotalk for its IPO, while driving strategic investments, international expansion, and long-term growth. 'As we are scaling and launching in new geographies, our finances have also started becoming more complex. We wanted a strong leader with good pedigree and experience who could handle our finances with airtight compliance,' said founder and chief executive Puneet Gupta. Astrotalk operates on a revenue-sharing model with more than 20,000 active astrologers on its platform. It also has over 700,000 daily active users. The company's pricing structure ranges from Rs 10 to Rs 200 per minute. According to Astrotalk, it is operating at a revenue run-rate of Rs 1,600 crore. The company saw its operating revenue for FY24 more than double to Rs 651 crore as it expanded its presence in domestic and international markets. Its net profit increased more than ten-fold to Rs 94 crore for the year ended March 2024. It is yet to file financial statements for FY25 with the Registrar of Companies.'Preparing for an IPO is like preparing for a marathon, it requires precision, strategy, and the right team. I look forward to building the financial discipline and systems that will support the company's ambitions for years to come,' said Khetan. The company said it aims to generate 40% of its revenue from overseas markets in the coming years. Astrotalk last raised $14 million last year in a funding round led by Elev8 Venture Partners at a valuation of about Rs 2,500 crore ($300 million). Elevate your knowledge and leadership skills at a cost cheaper than your daily tea. IndiGo's GIFT City unit: Simple expansion or is there more to it than meets the eye? GST cut to benefit; but who gains the most? Good, bad, ugly: How will higher ethanol in petrol play out for you? Why are mid-cap stocks fizzling out? It's not just about Trump tariffs. Stock Radar: This hotel stock is showing signs of bottoming out; time to buy? Logistics sector: Be tactical in the face of head & tailwinds; 6 logistics stocks with an upside potential of over 30% Stock picks of the week: 5 stocks with consistent score improvement and return potential of more than 25% in 1 year History of wealth creators: Everything should be in context, whether it is PE or PEG; on a standalone basis they mean nothing
Economic Times
11 minutes ago
- Economic Times
Perplexity to provide users live earnings call transcriptions for Indian stocks
Synopsis US-based AI firm Perplexity has enhanced its Finance dashboard with live transcriptions and earnings call schedules for Indian companies. Following its launch of free access to Indian stock data, the move aims to simplify market research. Perplexity also partnered with Airtel to offer its AI search tool to millions of users.
